Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy

CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.

Trial Details

NCT ID
NCT06880029
Phase
PHASE1 / PHASE2
Sponsor
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Morning pembrolizumab infusions
Locations (sample)
  • Vila Nova de Gaia, Região, Portugal|41.12401,-8.61241

Key Eligibility Criteria

  • Female sex
  • Age 18 - 75 years old
  • Diagnosed with Stage II or III TNBC and candidates for neoadjuvant treatment with ChT+pembrolizumab after multidisciplinary group discussion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →